Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTM-H-001 in Relapsed or Refractory B-cell Malignancies
NCT07476378Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTM-H-001 in B cell lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence of Dose-Limiting Toxicity at 42 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
MTM-H-001
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07476378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476378.